Page 6 - egyben_egyetemi_techn
P. 6
hnology Offer Fine Tuning of Anti-Scl-70 Immunoassay
Keywords: laboratory diagnostics, autoimmune disease, topoisomerase, Scl-70
Background
Field of technology: Systemic sclerosis is a systemic autoimmune disorder charac-
terized manly by skin fibrosis. The vast majority of patients have anti-nuclear antibo-
dies present in their serum, which predominantly recognizes DNA topoisomerase I.
Challenge: Diagnosis of systemic sclerosis can be challenging especially in the early
stage. The presence of anti-topoisomerase I antibodies (Scl-70) is one of the main
early indicators but not enough for differential diagnosis. Here we offer fragments of
topoisomerase I for fine tuning the autoantibody detection.
Brief description
The present invention relates to the two
fragments of human topoisomerase I that
epitopes serve as early stage prognostic
markers for diffuse cutaneous scleroderma
and systemic lupus erythematosus. The
protein fragments are synthesized in large
amount and high purity with fusion tags
allowing surface immobilization. Thus
are ready to be used in any downstream
immunoassay applications. In addition
to the conventional anti-Scl-70 assay
our fragments can provide significant
prognostic value to the diagnosis.
Selected Applications
High performance diagnostic auto-antibody detection from serum by ELISA
IP Status: Patent (Hungarian) granted, filed PCT and national phase in Japan, USA,
and Europe.
We are seeking for: Licensing
Technology Transfer Office
University of Pécs
Vasvári Pál u. 4.
H-7622 Pécs, HUNGARY
www.innovation.pte.hu
phone: +36 72 50 15 00 / 12292
mobile: +36 30 28 87 076
e-mail: kttk@pte.hu
All Intellectual Property rights reserved by University of Pécs
Keywords: laboratory diagnostics, autoimmune disease, topoisomerase, Scl-70
Background
Field of technology: Systemic sclerosis is a systemic autoimmune disorder charac-
terized manly by skin fibrosis. The vast majority of patients have anti-nuclear antibo-
dies present in their serum, which predominantly recognizes DNA topoisomerase I.
Challenge: Diagnosis of systemic sclerosis can be challenging especially in the early
stage. The presence of anti-topoisomerase I antibodies (Scl-70) is one of the main
early indicators but not enough for differential diagnosis. Here we offer fragments of
topoisomerase I for fine tuning the autoantibody detection.
Brief description
The present invention relates to the two
fragments of human topoisomerase I that
epitopes serve as early stage prognostic
markers for diffuse cutaneous scleroderma
and systemic lupus erythematosus. The
protein fragments are synthesized in large
amount and high purity with fusion tags
allowing surface immobilization. Thus
are ready to be used in any downstream
immunoassay applications. In addition
to the conventional anti-Scl-70 assay
our fragments can provide significant
prognostic value to the diagnosis.
Selected Applications
High performance diagnostic auto-antibody detection from serum by ELISA
IP Status: Patent (Hungarian) granted, filed PCT and national phase in Japan, USA,
and Europe.
We are seeking for: Licensing
Technology Transfer Office
University of Pécs
Vasvári Pál u. 4.
H-7622 Pécs, HUNGARY
www.innovation.pte.hu
phone: +36 72 50 15 00 / 12292
mobile: +36 30 28 87 076
e-mail: kttk@pte.hu
All Intellectual Property rights reserved by University of Pécs
